Oteseconazole

In this issue we will present synthetic strategies towards the synthesis of oteseconazole, designed to inhibit fungal CYP51, which is required for fungal cell wall integrity, and being this selective interaction also toxic to fungi, resulting in the inhibition of fungal growth. Due to its chemical structure, oteseconazole has a lower affinity for human CYP enzymes as compared to fungal CYP enzymes and has been indicated for the treatment of recurrent vulvovaginal candidiasis (RVVC) and developed by Mycovia Pharmaceuticals. RVVC, also known as chronic yeast infection, is defined by the Centers for Disease Control and Prevention (CDC) as three or more symptomatic acute episodes of yeast infection in 12 months. RVVC is a distinct condition from vulvovaginal candidiasis (VVC), and until now, there have been no FDA-approved medications specifically indicated for it. Nearly 75% of all adult women will have at least one yeast infection in their lifetime, with approximately half experiencing a recurrence. Of those women, up to 9% develop RVVC. Oteseconazole sold under the brand name Vivjoa was approved on 26th of April 2022.